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The goal of ‘‘personalised’’ medicine has seen a growing interest in
the development of theranostic agents. Bifunctional, and targeted-
trifunctional, theranostic water-soluble porphyrins with a histidine-
like chelating group have been synthesised via copper-catalysed
azide–alkyne cycloaddition (CuAAC) ‘‘click’’ chemistry in high yield
and purity. They are capable of photodynamic treatment and
[99mTc(CO)3]
+ complexation for single-photon emission computed
tomography (SPECT) imaging, with a radiochemical yield of 495%.
The toxicity and phototoxicity were evaluated on HT-29 cells, DU145,
and DU145-PSMA cell lines, with the targeted theranostic showing
more potent phototoxicity towards DU145-PSMA expressing cells.
Theranostics, a term given to the combination of therapy
(thera-) and diagnostic (-nostic) modalities into a single con-
struct or molecule, has seen a growing interest in the field of
medicine.1,2 Conventional treatments often involve a ‘‘one-size-
fits-all’’ technique, and can have significant differences in the
treatment outcomes between patients. Theranostics naturally
lends itself towards the goal of ‘‘personalised’’ medicine, cap-
able of optimising and improving treatment outcomes.1
Porphyrins are excellent candidates for molecular theranostic
agents. There are multiple studies documenting their use in
medicine, especially as a photosensitiser in the field of photo-
dynamic therapy (PDT).1,2 Porphyrins, when combined with
molecular oxygen and visible light (400–700 nm), are capable of
delivering potent and selective photodynamic treatment to
tumour tissues.1,3–5 By combining a diagnostic modality with
a PDT drug, this allows the careful monitoring of the accumu-
lation of PDT drug within the body, facilitating the tuning of
treatment by light irradiation when the accumulation of drug is
at a maximum, ultimately improving treatment outcomes.
Single-photon emission computed tomography (SPECT) is
a highly sensitive imaging technique that requires the admin-
istration of a radiotracer. SPECT requires the radiotracer
to biodistribute/accumulate in the body. Images are then
obtained using a gamma camera and computed to provide a
3D image of the location of the radiotracer in the body. 99mTc is
often used in SPECT imaging, since it has desirable nuclear
properties with a half-life, t1/2, of 6 hours and a main gamma
emission, Eg, at 140 keV (89% emission).
6 Its half-life is long
enough to manipulate the isotope to prepare various radio-
pharmaceuticals and its gamma emission allows established
chemistry. Its availability from a 99Mo/99mTc generator and
relative low cost, have made it the most commonly used radio-
isotope in diagnostic nuclear medicine.6
Schibli has shown that alkyne/azide-modified amino acids
‘‘click’’, via copper-catalyse azide alkyne cycloaddition (CuAAC),
with other azide/alkyne-functionalised molecules, to form a
histidine-like structure that can efficiently complex [99mTc(CO)3]
+.7
The utilisation of ‘‘click’’ chemistry unlocks the possibility to
use a high yielding and high purity ‘‘click’’ reaction to combine
two moieties together, opening the way towards molecular
SPECT theranostic medicine.
Despite the potential utility of 99mTc-labelled porphyrins,
there are limited reports on the combination of PDT with
SPECT,8–13 with only one example on the usage of conjugated
histidine-like structures as a 99mTc chelate.13 Herein, following
our interest in developing porphyrin molecular theranostics,14–17
we report the synthesis of two water-soluble porphyrins con-
jugated with histidine-like ligands using CuAAC ‘‘click’’ chem-
istry in high yields and with minimal impurities, and show that
they are capable of complexing [99mTc(CO)3]
+ with good radio-
chemical yields.
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Initially, a water-soluble azide-appended porphyrin 1 was
synthesised via 5 steps as previously reported (detail in ESI†).18
Commercially available D-propargylglycine was conjugated
with porphyrin 1 using CuAAC (Scheme 1).19 With excess
D-propargylglycine, quantitative conversion of porphyrin 1 to
conjugate 2 was shown using HPLC analysis, with a clear shift
in HPLC retention time from 10.8 min to 7.5 min (Fig. S1A,
ESI†). Subsequently, purification of conjugate 2 was carried out
using a counter-ion exchange technique previously reported by
our group.14 Briefly, the solubility of the porphyrin can be
controlled by exchanging the anionic counter-ions. Exchange
of the iodide anions with hexafluorophosphate rendered the
conjugate insoluble in water. This allowed filtration and
removal by washing of excess starting materials and reagents.
Subsequent anionic conversion to chloride yielded the water-
soluble conjugate 2. The identity of conjugate 2 was further
confirmed using NMR and mass spectrometry.
We envisaged introduction of an additional targeted func-
tionality could be facilitated by using lysine, instead of glycine,
which has an amino group side chain. However, there is no
commercially available propargyl lysine, hence, modification
of commercially available N(e)-Boc-Lys(OMe) was required.
Scheme 2 shows the modification of N(e)-Boc-Lys(OMe)
to introduce an alkyne-functionality and also a conjugatable
linker, 5. This linker allows further conjugation with a targeting
moiety. We have chosen a well-described small molecule
dipeptide that acts as an inhibitor against prostate specific
membrane antigen (PSMA), which is overexpressed in meta-
static prostate cancer.20 The targeting dipeptide has the
structure: lysine-urea-glutamate, with the glutamate moiety
responsible for targeting and binding to the pharmacophore
pocket of PSMA.21,22 Peptide conjugation and subsequent
deprotection of tert-butyl groups using trifluoroacetic acid
(TFA) yielded the clickable 6 capable of targeting PSMA.
Using similar CuAAC reaction conditions for the synthesis of
conjugate 2, quantitative conversion of porphyrin 1 to 3 was
observed, with a clear shift in HPLC retention time from 10.8 to
8.6 min (Fig. S1B, ESI†). Using the same counter-ion exchange
technique, 3 was purified, isolated, and characterised. Deprotec-
tion of methyl ester on 3 was carried out in aqueous LiOH yielding
trifunctional water-soluble conjugate 4 in quantitative yield.
Chemically and physically similar rhenium was complexed
with conjugate 2 and 4 (Scheme 1).23,24 Rhenium is a commonly
used surrogate for technetium as there is no stable technetium
isotopes.25 In addition, the availability of b-particle emitting
rhenium 186/188 isotopes further expand the utility of 2 and 4
as radiotherapeutic agent.26 Complexation with rhenium was
carried out to produce non-radioactive complexes for use as
HPLC standards and in biological cytotoxicity evaluations. With
a slight excess of rhenium at 65 1C for 2 hours, HPLC analysis of
the reaction mixture showed quantitative conversion of con-
jugates 2 and 4 to their corresponding complexes, [Re(2)] and
[Re(4)], exhibited by a clear shift in HPLC with retention times
Scheme 1 Synthesis of conjugate 2 and conjugate 3 and the subsequent complexation of natural rhenium and 99mTc. (i) 1 : 1 t-butanol : water,
D-propargylglycine, CuSO4, sodium ascorbate, microwave (20 min, 75 W, 50 1C). (ii) 6, 1 : 1 t-butanol : water, CuSO4, sodium ascorbate, tris[(1-benzyl-1H-
1,2,3-triazol-4-yl)methyl]amine, microwave (3 hours, 75 W, 70 1C). (iii) water, LiOH, room temperature 3 hours. (iv) phosphate buffer pH 7,
[Re(CO)3Br3][NEt4]2, 65 1C, 2 hours. (v) [
99mTc(CO)3(H2O)3]
+, pH 7.4, 90 1C, 30 min.
Scheme 2 Synthesis of trifunctional-propargyl lysine. (i) DMF, K2CO3,
propargyl bromide, room temperature, 48 hours. (ii) DCM, TFA, room
temperature, 2 hours. (iii) DMF, disuccinimidyl suberate, triethylamine,
room temperature, overnight. (iv) DMF, triethylamine, PSMA-dipeptide
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of 10.2 min and 10.8 min, respectively (Fig. S1, ESI†). 13C NMR
spectroscopy showed the addition of three carbonyl carbon
peaks between d 197–199 for both complexes, [Re(2)] and
[Re(4)]. High resolution mass spectrometry of [Re(2)] and
[Re(4)] also gave their corresponding mass peak, giving evi-
dence for the successful complexation of rhenium.
Successful synthesis of conjugate 2 and 4 and their corres-
ponding rhenium complexes prompted the radiolabelling with
99mTc. Firstly, [99mTc(CO)3(H2O)3]
+ was prepared according to
the literature method (Fig. S2 and S3, ESI†).27 After careful
optimisation of reaction conditions–reaction time, pH, reaction
temperature, and conjugate concentration, both conjugate 2
and 4 can be produced in 495% radiochemical yield (RCY) at a
concentration of 150 mM at pH 7.4, 99 1C for 30 min, as
determined using radio-HPLC. Radio-HPLC analysis showed
the formation of a single radiolabelled product which matches
well with the retention time of the rhenium complexes (Fig. 1),
giving evidence for the formation of the desired radiolabelled
complexes, [99mTc(2)] and [99mTc(4)]. With these optimised
radiolabelling conditions, specific activities of 76 GBq mmol1
and 96 GBq mmol1 were achieved for conjugates 2 and 4,
respectively. The lipophilicity of the tracers were determined
using the shake-flask method and were found to be 0.57 
0.08 and 1.31  0.01 for [99mTc(2)] and [99mTc(4)], respec-
tively. This indicates [99mTc(4)] is more hydrophilic due to the
presence of extra carboxylate groups.
The stability of the radiolabelled complexes, [99mTc(2)] and
[99mTc(4)], were tested against 50% foetal bovine serum (FBS)
with an activity of 35–40 MBq (at concentration of 460–530 nM
for [99mTc(2)] and 360–420 nM for [99mTc(4)]). [99mTc(2)] shows
94% of 99mTc still associated and [99mTc(4)] shows remarkable
stability against 50% FBS with 499% 99mTc still associated after
incubation for 6 hours (Fig. 2). The high serum stability of these
99mTc conjugates was expected as literature has shown the stability
of histidine and histidine-like complexes against serum.7,25,28
Toxicity and phototoxicity of 2 and [Re(2)] were evaluated on
human adenocarcinoma (HT-29) cells. Cells were incubated
with 2 and [Re(2)] at varying concentrations (1–18 mM) for
1 hour and irradiation was carried out using a constant dose
of visible light (20 J cm2; 400–700 nm). The results obtained
were compared with a non-irradiated control. Under these
conditions, both conjugate 2 and [Re(2)] were capable of inducing
450% cell death at 4.5 mM with minimal dark toxicity observed in
the non-irradiated controls (Fig. 3 and Fig. S6, ESI†).
As 4 and [Re(4)] have a targeting molecule which inhibits
PSMA, two different human prostate cancer cell lines were used
to evaluate the toxicity and phototoxicity of 4 and [Re(4)],
namely DU145, which does not express PSMA, and DU145-
PSMA, a PSMA-expressing variant.29 Initially, the level of PSMA
expression on both cell lines was determined by flow cytometry
analysis (Fig. S5, ESI†). Varying concentration of 4 and [Re(4)]
(1.5–24 mM) were incubated with these cell lines for 30 min
prior to visible light irradiation. Results obtained were also
compared with non-irradiated controls (Fig. 3 and Fig. S6,
ESI†). Without irradiation, both 4 and [Re(4)] show minimal
toxicity at these concentration with more than 86% cell survival
in both DU145 and DU145-PSMA. Under irradiation with visible
light, both 4 and [Re(4)] were capable of inducing death in both
DU145 and DU145-PSMA cells, with more potent phototoxicity
towards DU145-PSMA. At a concentration of 6 mM, 85% cell
survival was observed for 4 in DU145 cells with light irradiation,
while only 17% cell survival was observed in DU145-PSMA cells
under similar conditions. Similarly, [Re(4)] showed minimal
phototoxicity towards DU145 cells at a concentration of 1.5 mM
with 490% cell survival, but was capable of inducing near 70%
cell death in DU145-PSMA under similar conditions. These
results show, 4 and [Re(4)] are capable of inducing greater cell
death in DU145-PSMA cells compared to DU145 cells under
similar conditions. This is due to the overexpression of PSMA
on DU145-PSMA, resulting in the higher binding/uptake of 4
and [Re(4)] into DU145-PSMA.
Nevertheless, phototoxicity of 4 and [Re(4)] towards native
DU145 increases with concentration (Fig. 3 and Fig. S6, ESI†). This
could be due to a combination of low level native expression of
PSMA on DU145 and non-specific uptake/binding of 4 and [Re(4)].
In conclusion, the synthesis and evaluation of [99mTc(2)] and
[99mTc(4)] show the validity of a click to chelate method to
Fig. 1 Overlays of radio-HPLC of [99mTc(2)] and [99mTc(4)] and UV-vis
HPLC chromatograms [Re(2)] and [Re(4)]. Reaction conditions: [L] = 150 mM,
t = 30 min, T = 99 1C, pH 7.4.
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bifunctional theranostic and trifunctional targeted theranostic
agents. Excellent radiochemical yields (495%) were achieved
for radiolabelling of both 2 and 4. Individually, 2, [Re(2)], 4, and
[Re(4)] were capable of inducing cell death (490%) when
irradiated with light while showing minimal toxicity in the
absence of light. Specificity of 4 and [Re(4)] towards PSMA was
confirmed as more cell death was induced in DU145-PSMA
when compared to the DU145 under similar conditions. The
utilisation of CuAAC ‘‘click’’ chemistry demonstrated an effec-
tive strategy for combining different moieties into a single
molecule, providing a route towards multifunctional 99mTc
labelled porphyrin PDT/SPECT theranostic agents. This strategy
will allow the possibility of molecular multifunctional por-
phyrin agents to be applied in in vivo and clinical settings.
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